Related Experiment Video
Updated: Jun 29, 2025
04:59
Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
210
Hyperbaric oxygen therapy for poststroke insomnia: a systematic review and meta-analysis protocol.
Rui Shi1, Wenyi Meng2, Zhaozheng Liu2
1Changchun University of Chinese Medicine, Changchun, Jilin, China.
BMJ Open
|March 29, 2024
Summary
This systematic review will evaluate hyperbaric oxygen therapy (HBOT) for post-stroke insomnia. It aims to clarify HBOT
Area of Science:
- Neurology
- Sleep Medicine
- Cardiovascular Research
Background:
- Insomnia is a common complication following cerebrovascular events, impacting cognitive function and recovery.
- Existing randomized controlled trials (RCTs) on hyperbaric oxygen therapy (HBOT) for post-stroke insomnia have not definitively established its benefits or risks.
Purpose of the Study:
- To systematically review and meta-analyze RCTs to assess the efficacy and safety of HBOT for treating insomnia after stroke.
- To provide a comprehensive evaluation of HBOT's role in managing post-stroke sleep disturbances.
Main Methods:
- A systematic search of nine major databases will be conducted for RCTs on HBOT for post-stroke insomnia, published in English and Chinese up to November 1, 2023.
- Two independent reviewers will select studies, extract data, and assess quality using Cochrane Collaboration tools.
- Meta-analysis will be performed using RevMan V.5.4 and STATA V.16.0.b, with evidence quality assessed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method.
Main Results:
- Primary outcome: change in sleep quality.
- Secondary outcomes: adverse events and recurrence rates.
- The review will synthesize data from eligible RCTs to determine treatment effectiveness and safety profiles.
Conclusions:
- This systematic review and meta-analysis will offer crucial insights into the effectiveness and safety of HBOT for post-stroke insomnia.
- Findings will guide clinical practice and future research directions regarding HBOT interventions for stroke survivors with sleep disturbances.
More Related Videos
Related Concept Videos
01:19Management of Insomnia
244
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244
01:27Insomnia
85
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
85
01:14CNS Depressants: Barbiturates and Benzodiazepines
259
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
259
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
206
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
206
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
171
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
171
01:23Sedatives and Hypnotics: Overview
358
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
358